Nat Med: The safety and pharmacokinetics of enratravir subcutaneous implantation therapy for HIV-1 prevention

Enratrovir (MK-8591) is a highly effective type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life and is being developed for prevention and treatment HIV-1
.

Immunization prevention

Recently, the top medical journal Nature Medicine published a research article in which researchers conducted a randomized, double-blind, placebo-controlled phase 1 trial in adults who were not infected with HIV-1
.

Participants received 12 weeks of subcutaneous implantation of enratrovir or placebo and were monitored during the entire period and after the implant was removed

Infect

The common primary endpoint of the study is the safety and tolerability and pharmacokinetics of itratrovir after implantation, including the concentration of itratrovir triphosphate in peripheral blood mononuclear cells (PBMC) on day 85
.

Secondary endpoints include the additional pharmacokinetic parameters of elatrovir triphosphate in PBMC and the plasma pharmacokinetic characteristics of elatrovir

Based on preclinical data, the researchers evaluated two doses: 54 mg (n=8, two placebos) and 62 mg (n=8, two placebos)
.

The most frequently reported adverse events were mild to moderate implant site reactions (induration, hematoma, pain)

It can be seen that the two doses of elatrovir implantation treatment are safe, and the average concentration can be higher than the pharmacokinetic threshold within 12 weeks, so further research is needed to evaluate the effect of elatrovir implantation treatment The effectiveness of potential HIV prevention strategies
.

Both doses of ilatrovir implantation therapy are safe, and the average concentration can be higher than the pharmacokinetic threshold within 12 weeks, so further research is needed to evaluate ilatrovir implantation therapy as a potential HIV prevention strategy The effect
.

Original source:

Original source:

Randolph P.

Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial in this message